skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Talpaz, Moshe ; Kiladjian, Jean-Jacques

Leukemia, 2021-01, Vol.35 (1), p.1-17 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
2
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Material Type:
Artigo 		Adicionar ao Meu Espaço

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Schwartz, Daniella M ; Kanno, Yuka ; Villarino, Alejandro ; Ward, Michael ; Gadina, Massimo ; O'Shea, John J

Nature reviews. Drug discovery, 2017-12, Vol.16 (12), p.843-862 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
3
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Genovese, Mark C ; Fleischmann, Roy ; Combe, Bernard ; Hall, Stephen ; Rubbert-Roth, Andrea ; Zhang, Ying ; Zhou, Yijie ; Mohamed, Mohamed-Eslam F ; Meerwein, Sebastian ; Pangan, Aileen L

The Lancet (British edition), 2018-06, Vol.391 (10139), p.2513-2524 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Burmester, Gerd R ; Kremer, Joel M ; Van den Bosch, Filip ; Kivitz, Alan ; Bessette, Louis ; Li, Yihan ; Zhou, Yijie ; Othman, Ahmed A ; Pangan, Aileen L ; Camp, Heidi S

The Lancet (British edition), 2018-06, Vol.391 (10139), p.2503-2512 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

Vannucchi, Alessandro M ; Sordi, Benedetta ; Morettini, Alessandro ; Nozzoli, Carlo ; Poggesi, Loredana ; Pieralli, Filippo ; Bartoloni, Alessandro ; Atanasio, Alessandro ; Miselli, Filippo ; Paoli, Chiara ; Loscocco, Giuseppe G ; Fanelli, Andrea ; Para, Ombretta ; Berni, Andrea ; Tassinari, Irene ; Zammarchi, Lorenzo ; Maggi, Laura ; Mazzoni, Alessio ; Scotti, Valentina ; Falchetti, Giorgia ; Malandrino, Danilo ; Luise, Fabio ; Millotti, Giovanni ; Bencini, Sara ; Capone, Manuela ; Piccinni, Marie Pierre ; Annunziato, Francesco ; Guglielmelli, Paola

Leukemia, 2021-04, Vol.35 (4), p.1121-1133 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
6
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis

Krueger, James G. ; McInnes, Iain B. ; Blauvelt, Andrew

Journal of the American Academy of Dermatology, 2022-01, Vol.86 (1), p.148-157 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
7
Abrocitinib: First Approval
Abrocitinib: First Approval
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abrocitinib: First Approval

Deeks, Emma D. ; Duggan, Sean

Drugs (New York, N.Y.), 2021-12, Vol.81 (18), p.2149-2157 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por
8
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

Pardanani, Animesh ; Tefferi, Ayalew ; Masszi, Tamás ; Mishchenko, Elena ; Drummond, Mark ; Jourdan, Eric ; Vannucchi, Alessandro ; Jurgutis, Mindaugas ; Ribrag, Vincent ; Rambaldi, Alessandro ; Koh, Liang Piu ; Rose, Shelonitda ; Zhang, Jun ; Harrison, Claire

British journal of haematology, 2021-10, Vol.195 (2), p.244-248 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
9
Delgocitinib: First Approval
Delgocitinib: First Approval
Material Type:
Artigo 		Adicionar ao Meu Espaço

Delgocitinib: First Approval

Dhillon, Sohita

Drugs (New York, N.Y.), 2020-04, Vol.80 (6), p.609-615 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por
10
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Material Type:
Artigo 		Adicionar ao Meu Espaço

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

Nogueira, Miguel ; Puig, Luis ; Torres, Tiago

Drugs (New York, N.Y.), 2020-03, Vol.80 (4), p.341-352 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (3.129)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (3.239)
  2. Book Chapters  (4)
  3. Anais de Congresso  (2)
  4. Web Resources  (1)
  5. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1999  (85)
  2. 1999Até2004  (342)
  3. 2005Até2010  (544)
  4. 2011Até2017  (1.240)
  5. Após 2017  (1.037)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (3.233)
  2. Japonês  (793)
  3. Russo  (4)
  4. Chinês  (4)
  5. Alemão  (4)
  6. Francês  (3)
  7. Polonês  (1)
  8. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.